Case report: apatinib plus selexipag as a novel therapy for pulmonary tumor thrombotic microangiopathy accompanied by pulmonary hypertension associated with gastric carcinoma.
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000029412
Abstract: RATIONALE PTTM is a rare but fatal disease, characterized by endothelial intimal proliferation and pulmonary hypertension due to micro-vascular remodeling. In view of the poor prognosis, new effective strategies are urgently required. PATIENT CONCERNS AND… read more here.
Keywords: pulmonary hypertension; hypertension; therapy; case report ... See more keywords
Apatinib plus paclitaxel versus paclitaxel monotherapy for platinum‐resistant recurrent ovarian cancer treatment: A retrospective cohort study
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Pharmacy and Therapeutics"
DOI: 10.1111/jcpt.13806
Abstract: Apatinib, an oral antiangiogenic drug, exerts potential anti‐tumour effects on platinum‐resistant recurrent ovarian cancer (PROC). This study intended to evaluate the efficacy and safety of apatinib plus paclitaxel compared to paclitaxel monotherapy in PROC patients. read more here.
Keywords: recurrent ovarian; platinum resistant; ovarian cancer; apatinib plus ... See more keywords
Efficacy of the Low Dose Apatinib plus Chemotherapy on Advanced Gastric Carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Oncology"
DOI: 10.1155/2022/3009494
Abstract: Objective To evaluate the efficacy of low dose apatinib plus chemotherapy on advanced gastric carcinoma. Methods Eligible 50 patients with advanced gastric carcinoma admitted to the hospital from January 2019 to March 2020 were enrolled,… read more here.
Keywords: plus chemotherapy; advanced gastric; apatinib plus; group ... See more keywords
Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study
Sign Up to like & getrecommendations! Published in 2022 at "Disease Markers"
DOI: 10.1155/2022/4322404
Abstract: Background Apatinib is established to be the standard of care as third-line therapy for patients with previously treated advanced gastric cancer (GC). Programmed cell death protein 1 (PD-1) blockades also exhibited promising efficacy and safety… read more here.
Keywords: treated advanced; plus inhibitors; previously treated; apatinib plus ... See more keywords
Apatinib plus vinorelbine: A novel combination of all-oral regimen in heavily pretreated patients with metastatic HER2-negative breast cancer.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e13096
Abstract: e13096Background: Antiangiogenic therapy in combination with chemotherapy is effective in control advanced breast cancer. Apatinib is an oral highly potent tyrosine kinase inhibitor targeting vascu... read more here.
Keywords: combination; apatinib plus; cancer apatinib; breast cancer ... See more keywords
Apatinib plus vinorelbine versus vinorelbine for advanced triple-negative breast cancer with failed first or second-line treatment: The NAN trial.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.1075
Abstract: 1075 Background: No standard treatment exists for triple negative breast cancer (TNBC) with failure of multi-line therapies. Apatinib is a small-molecule tyrosine kinase inhibitor that has promising anti-angiogenesis and antitumor activity for TNBC. We aimed… read more here.
Keywords: line; treatment; plus vinorelbine; apatinib plus ... See more keywords
Conversion hepatectomy for hepatocellular carcinoma with inadequate future- remnant- liver after portal vein ligation in combination with apatinib plus camrelizimab: A single-arm prospective pilot study (PLACES).
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.e16132
Abstract: e16132 Background: A variety of staged hepatic resection has been applied in patients (pts) with hepatocellular carcinoma (HCC) who had an inadequate future-remnant-liver (FRL), but the clinical outcomes remain unsatisfactory. Based on the clinical data… read more here.
Keywords: hepatocellular carcinoma; plus camrelizimab; treatment; apatinib plus ... See more keywords
Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2021.835889
Abstract: Objective This study was conducted in order to compare the efficacy and safety of transarterial chemoembolization (TACE) plus apatinib plus camrelizumab (TACE+AC) and apatinib plus camrelizumab (AC) in the treatment of unresectable hepatocellular carcinoma (HCC)… read more here.
Keywords: hepatocellular carcinoma; plus camrelizumab; apatinib plus; group ... See more keywords
Apatinib combined with PD-1 antibody for third-line or later treatment of advanced gastric cancer
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.952494
Abstract: Background Both apatinib and programmed death 1 (PD-1) monoclonal antibody (mAb) monotherapy have been licensed in China for the third-line treatment of advanced gastric cancer (AGC). However, whether the combination could improve the prognosis of… read more here.
Keywords: apatinib; apatinib plus; monotherapy; plus mab ... See more keywords
Evaluation of second-line apatinib plus irinotecan as a treatment for advanced gastric adenocarcinoma or gastroesophageal conjunction adenocarcinoma: a prospective, multicenter phase II trial
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2023.1072943
Abstract: Objective Apatinib and irinotecan are used as systematic therapies for advanced gastric adenocarcinoma (GAC) and gastroesophageal junction adenocarcinoma (GEJA), while the evidence for their combination as second-line therapy in these patients is limited. This study… read more here.
Keywords: apatinib; apatinib plus; second line; treatment ... See more keywords
Efficacy, safety, and prognostic factors of apatinib plus platinum doublet chemotherapy in advanced non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Cancer Research and Therapeutics"
DOI: 10.4103/jcrt.jcrt_1853_21
Abstract: Background: Anti-angiogenesis drugs are applicable in treating advanced non-small cell lung cancer (NSCLC); however, the related data regarding apatinib, a Chinese domestic anti-vascular endothelial growth factor receptor-2 (VEGFR-2) production, are limited. Therefore, this study explored… read more here.
Keywords: apatinib plus; plus platinum; doublet chemotherapy; platinum doublet ... See more keywords